Marina Konopleva, M.D., Ph.D.- Professor, Department of Oncology (Medical Oncology) Professor, Department of Molecular Pharmacology- Albert Einstein College of Medicine
In this presentation by Marina Konopleva, MD, she covers the resistance mechanisms and potential combination strategies related to venetoclax, an AML (acute myeloid leukemia) treatment. Despite overlapping slides, she delves into the topic, shedding light on resistance challenges. Konopleva elaborates on the mechanism of action, targeting BCL-2, and its interaction with mitochondrial proteins.
REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/
AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/
The presentation highlights the impact of monocytic leukemia, refuting the notion that it universally resists venetoclax, emphasizing the significance of genotypic influences. Additionally, she discusses the emergence of resistance patterns with PPM1D mutations, providing insights into ongoing trials